

Gilead Sciences - 2022 Transfers of value to HCPs and HCOs

Date of publication: 30/06/2023

	Full Name (Art. 1.01)	HCPs: City of Principal Practice / HCOs: City where registered (Art. 3)	Country of Principal Practice (Schedule 1)	Principal Practice Address (Art. 3)	Unique country identifier OPTIONAL (Art. 3)	Donations and Grants to HCOs / (Art. 3.01.1.a)	Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract		
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.)												
	OTHER, NOT INCLUDED ABOVE- (where information cannot be disclosed on an individual basis for legal reasons)												
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02												
	Number of Recipients in aggregate disclosure - Art 3.02												
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02												
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.)												
	Landspítali University Hospital	Reykjavik	Iceland	Reykjafold 4						266 752 ISK		266 752 ISK	
	OTHER, NOT INCLUDED ABOVE- (where information cannot be disclosed on an individual basis for legal reasons)												
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02												
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02						0%	0%	0%	0%	0%		0%
R&D	AGGREGATE DISCLOSURE												
	Transfers of Value re Research & Development as defined in Article 3.04 and Schedule 1									28 458 209 ISK	28 724 961 ISK		